SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

• Main Authors: Robert T Jacobs (Author), Bakela Nare (Author), Stephen A Wring (Author), Matthew D Orr (Author), Daitao Chen (Author), Jessica M Sligar (Author), Matthew X Jenks (Author), Robert A Noe (Author), Tana S Bowling (Author), Luke T Mercer (Author), Cindy Rewerts (Author), Eric Gaukel (Author), Jennifer Owens (Author), Robin Parham (Author), Ryan Randolph (Author), Beth Beaudet (Author), Cyrus J Bacchi (Author), Nigel Yarlett (Author), Jacob J Plattner (Author), Yvonne Freund (Author), Charles Ding (Author), Tsutomu Akama (Author), Y-K Zhang (Author), Reto Brun (Author), Marcel Kaiser (Author), Ivan Scandale (Author), Robert Don (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2011-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals. An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor...